Cordarone® / Pacerone®
Amiodarone is a class III antiarrhythmic with properties of all Vaughan-Williams classes. Used for life-threatening ventricular arrhythmias.
| Dosage Form | Oral Tablet / IV Injectable |
| Strength | 100 mg, 200 mg, 400 mg (oral); 50 mg/mL (IV) |
| Storage | Store at 20–25°C. Protect from light. IV: Use within 24 hours of dilution. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Life-threatening recurrent ventricular fibrillation and hemodynamically unstable ventricular tachycardia refractory to other agents.
Multichannel blocker: primarily blocks potassium channels (class III), but also inhibits sodium channels (class I), calcium channels (class IV), and beta-adrenergic receptors (class II). Prolongs action potential and refractory period.
Each Burrard Pharmaceuticals technology transfer package for Amiodarone includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.